Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-13
2010-02-23
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S276000
Reexamination Certificate
active
07666901
ABSTRACT:
The present invention relates to compounds of formula I:wherein R1, R2, R3, and R8are defined herein.
REFERENCES:
patent: 5378725 (1995-01-01), Bonjouklian et al.
patent: 5468773 (1995-11-01), Dodge et al.
patent: 5480906 (1996-01-01), Creemer et al.
patent: 6670348 (2003-12-01), Rosen et al.
patent: 6703414 (2004-03-01), Powis et al.
patent: 2003/0109572 (2003-06-01), Powis
patent: 2003/0194749 (2003-10-01), Wandless et al.
patent: 2006/0063824 (2006-03-01), Kirkpatrick et al.
patent: 2 302 021 (1997-08-01), None
patent: WO 96/01108 (1996-01-01), None
patent: WO/01 00213 (2001-01-01), None
patent: WO/01 47921 (2001-07-01), None
patent: WO 03/024183 (2003-03-01), None
patent: WO/03 030909 (2003-04-01), None
patent: WO 2004/024093 (2004-03-01), None
patent: WO 2004/093918 (2004-11-01), None
Creemer, L.C., et al., “Synthesis and in Vitro Evaluation of New Wortmannin Esters: Potent Inhibitors of Phosphatidylinositol 3-Kinase” (1996)J. Med. Chem., vol. 39, No. 25,pp. 5021-5024.
De Luca, L., et al., “An Efficient Route to Alkyl Chlorides from Alcohols Using the Complex TCT/DMF” (2002)Organic Letters, vol. 4, No. 4, pp. 553-555.
Ihle, NT, et al., Abstract “95thAnnual Meeting of the American Association for Cancer Research,” Orlando, Florida, USA, Mar. 27-31, 2004.
Powis, G., et al., Abstract No. 4752 “Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinosito-3 kinase” Accession No. WD-2004-005811, Mar. 29, 2004.
Norman, B.H., et al., “Studies on the Mechanism of Phosphatidylinositiol 3-Kinase Inhibition by Wortmannin and Related Analogs,” (1996)J. Med. Chem., vol. 39, No. 5, pp. 1106-1111.
von Walter Haefliger, et al., Selektive Funktionalisierung von Wortmannin mit Hilfe einer Furanring-Maskierung, (1975)Helvetica Chimica Acta, vol. 58, No. 6. pp. 179-180.
Ihle, N.T., et al., “Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor or phosphoinositide-3-kinase signaling” (1996)Mol. Cancer Therapeutics, vol. 3, No. 7,pp. 763-772 (2004).
Ihle, N.T., et al., “The phosphatidylinositol-3-kinase inhibitor PS-866 over comes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts”Mol. Cancer Therapeutics, vol. 4, No. 9, pp. 1349-1357, (2005).
Pasut, G., et al., “Protein, peptide andnon-peptide drug PEGylation for therapeutic application,”Expert Opinion, vol. 14, No. 6, pp. 859-894 (2004).
von Walter Haefliger, et al., “Einiunrung der Corticoid-Seitenkette bei Wortmannin,”Helvetica Chimica Acta, vol. 58, No. 6. pp. 1629-1633, (1975).
Wipf, P., et al., “Synthesis and biological evaluation of synthetic viridins derived from C(20) -heteroalkylation of the steroidal PI-3-kinase inhibitor,”Org. Biomol. Chem., vol. 2, pp. 1911-1920, (2004).
Cai Ping
Gu Jianxin
Kaplan Joshua
Yu Ker
Zask Arie
Dentz Bernard
Rubin David
Wyeth
LandOfFree
Analogs of 17-hydroxywortmannin as PI3K inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogs of 17-hydroxywortmannin as PI3K inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of 17-hydroxywortmannin as PI3K inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155047